(Could not post the following on Yhoo board, seemingly blocked)
Folks, do not lose sight of the fact that Sanofi/Genzyme had a $1 billion renal franchise, top profit generator for company, dominated renal space for over a decade, global infrastructure in place — that franchise well into facing demise due to generics and industry
advancements.
Furthermore, Sanofi/Genzyme has known this was coming years ago. Have they, are they, just rolling over and playing dead with a top profit generator franchise in demise with global infrastructure in place and more than a decade dominating the renal space?
Look folks, if Vifor Fresenius got ahold of Auryxia and Vadadustat, AND Triferic, they would have a monopoly in the renal space sorta speak. This is not likely to happen, not on Sanofi/Genzyme watch — IMO.
Have not read or heard anything indicating Sanofi/Genzyme retiring from renal space. In fact, in their last quarterly cc, CEO Brandicourt spoke about having $7 billion for continued m&a. Furthermore., Sanofi/Genzyme is expected to close deal on sale of its EU generic division (Advent) for some $2.5 billion in upcoming months.
Now, can someone answer the following question — why does Keryx have so many ex-Sanofi/Genzyme execs and Directors (Regan/Enyedy) at Keryx (including the late Madison), mind you, all top Sanofi/Genzyme ex-execs involved in having built Renvela into a $1 billion renal franchise — why? Butler, along with Regan, Enyedy, Madison, all involved in buiding Renvela into a 1 billion top profit generator. Is Sanofi/Genzyme out of the picture — I say, no way.
Yesterday, “hooligan” Dave/Duke (Duke on the RMTI board, IMO), peddled alot of convoluted concoctions on this here board; personally, trust him like I trust Keryx/Akebia looking out for shareholders best interest — ZERO!
ALL above, in my opinion, as always..
